SOUTH SAN FRANCISCO, Calif., March 30 /PRNewswire-FirstCall/ -- Cell
Genesys, Inc. (Nasdaq: CEGE) today announced that each of its four submitted
abstracts have been accepted for presentation at the 2006 American Association
for Cancer Research (AACR) Annual Meeting which will take place in Washington,
DC, April 2 to 5. The four abstracts to be presented by Cell Genesys
scientists are as follows:
-- Humoral immune response induced to filamin B in patients with
metastatic hormone-refractory prostate cancer (HRPC) treated with a
GM-CSF-transduced allogeneic prostate cancer vaccine (GVAX(R)). (To be
presented in a poster discussion on Monday, April 3, 1:00 - 5:00 p.m.
EDT) (Abstract ID: 2894)
-- Local secretion of anti-CTLA-4 antibody from a GM-CSF-secreting tumor
cell vaccine enhances vaccine efficacy (To be presented in
mini-symposia on Sunday, April 2, 3:25 - 3:40 p.m. EDT)
(Abstract ID: 1520)
-- EGFR inhibitors decrease the potency of GM-CSF-secreting tumor cell
vaccines by inhibiting T-cell activation. (To be presented in a poster
discussion on Sunday, April 2, 1:00 - 5:00 p.m. EDT)
(Abstract ID: 1398)
-- An armed oncolytic vector (OV1203) expressing E. coli purine nucleoside
phosphorylase (PNP) combined with Fludara(TM) shows increased efficacy.
(To be presented in mini-symposia on Tuesday, April 4, 11:40 - 11:55
a.m. EDT) (Abstract ID: 4022)
Cell Genesys is focused on the development and commercialization of novel
biological therapies for patients with cancer. The company is currently
pursuing two clinical stage product platforms -- GVAX(R) cancer
immunotherapies and oncolytic virus therapies. Ongoing clinical trials
include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2
trials of GVAX immunotherapy for pancreatic cancer and leukemia, and a Phase 1
trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys
continues to hold an equity interest in its former subsidiary, Ceregene, Inc.,
which is developing gene therapies for neurodegenerative disorders. Cell
Genesys is headquartered in South San Francisco, CA and has its principal
manufacturing operation in Hayward, CA. For additional information, please
visit the company's website at http://www.cellgenesys.com.
Statements made herein about the company, other than statements of
historical fact, including statements about the company's progress, results
and timing of clinical trials and preclinical programs and the nature of
product pipelines are forward-looking statements and are subject to a number
of uncertainties that could cause actual results to differ materially from the
statements made, including risks associated with the success of clinical
trials and research and development programs, the regulatory approval process
for clinical trials, competitive technologies and products, patents,
continuation of corporate partnerships and the need for additional financings.
For information about these and other risks which may affect Cell Genesys,
please see the company's Annual Report on Form 10-K for the year ended
December 31, 2005 filed on March 13, 2006 as well as Cell Genesys' reports on
Form 10-Q and 8-K and other reports filed from time to time with the
Securities and Exchange Commission. The company assumes no obligation to
update the forward-looking information in this press release.
Contact: Ina Cu
Investor Relations
650-266-3200
SOURCE Cell Genesys, Inc.
 back to top
Related links:
http://www.cellgenesys.com
CONTACT:
Ina Cu, Investor Relations of Cell Genesys,
+1-650-266-3200
|
